AP-HP Hôpital Européen Georges-Pompidou | Cancer Care

Hôpital Européen Georges-Pompidou opened in 2000 as part of the reorganisation of hospital services in western Paris. It is an AP-HP public university hospital, bringing clinical care, medical education and research together within the French hospital system.

It is a large, multispecialty adult hospital rather than an institution devoted exclusively to cancer. Oncology services sit alongside medical, surgical, diagnostic and supportive services, which can be relevant when cancer treatment involves complex operations or significant coexisting illness.

The centre is known for digestive and urological oncology programmes, alongside thoracic cancer care. Relevant technical capabilities include molecular biology work involving circulating tumour DNA and interventional oncology. These describe areas of activity, not a promise that every procedure or test will be appropriate or available for every referral.

Digestive oncology includes colorectal and gastric cancers. Assessment considers the tumour’s location, stage, pathology and relevant molecular features, together with the patient’s general health. Depending on these findings, care may involve surgery, medicines, radiotherapy in selected situations, or a combination of approaches.

Urological oncology includes kidney and prostate cancers, where decisions can range from monitoring in selected circumstances to local treatment or systemic therapy. Lung cancer is another listed specialty, with treatment shaped by tumour subtype, extent of disease and biomarkers. These programmes are relevant to both newly diagnosed and previously treated patients, but the centre should confirm whether it can address a particular rare subtype, recurrence or complex second-opinion request.

Surgery forms part of the treatment portfolio for suitable patients. Whether an operation is advisable depends on resectability, expected benefit, fitness and alternative options. Patients should ask about the proposed procedure, recovery needs and how surgical decisions are reviewed with other oncology specialists.

Radiotherapy is also a listed treatment modality. It may be used for local disease control or symptom relief, depending on the diagnosis. Confirm the recommended technique, treatment location and number of visits rather than assuming that every component of care takes place in one department or building.

Systemic treatments include chemotherapy, immunotherapy and targeted therapy. Their use depends on the cancer type, stage, biomarkers, previous exposure and applicable prescribing arrangements. Precision oncology means using tumour characteristics to help guide treatment; it does not mean that a matched drug will necessarily be identified or funded.

The molecular biology platform includes circulating tumour DNA capabilities. Such blood-based testing may support selected clinical or research questions, but does not universally replace tissue biopsy. Interventional oncology uses image-guided procedures for selected indications. Ask which procedures are relevant to the case and how their benefits and risks compare with other options.

The available profile describes around 150 active oncology clinical trials. This is an indicative figure: study status changes, and active studies may include trials that have closed recruitment but continue treatment or follow-up. A current, diagnosis-specific trial search is more useful than the overall portfolio size.

International patients can ask for trial screening alongside a clinical case review. Eligibility may depend on pathology, molecular findings, previous treatments, organ function and the ability to attend repeated visits. Residency, coverage and administrative requirements also need checking. Trial participation is voluntary, involves informed consent and cannot be guaranteed; study-funded procedures do not necessarily cover routine care, travel or accommodation.

Before arranging travel, request confirmation that the relevant department will review the case and identify the appropriate referral route. Send a concise medical summary and ask whether remote document review is possible. A preliminary opinion may change after examination, pathology review or additional testing in Paris.

Agree who will coordinate care across countries. Clarify the expected time in France, likely need for a caregiver, emergency arrangements and how results will reach the home oncology team. Obtain written information about proposed care and payment responsibilities, and avoid non-refundable bookings until appointments and administrative requirements are confirmed.

Contact details below come from the hospital's own published international patient information.

Location: Paris, France

Email: No public international e-mail address is published; use the website enquiry form.

Phone: +33 1 56 09 20 00

Website: https://hegp.aphp.fr

Languages supported: French, English, Arabic

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.